Claire L Vale, Peter J Godolphin, David J Fisher, Julian P T Higgins, Alexandra McAleenan, Francesca Spiga, Tobias Tritschler, Pedro Gabriel Melo de Barros E Silva, David D Berg, Jeffrey S Berger, Lindsay R Berry, Behnood Bikdeli, Marc Blondon, Erin A Bohula, Marco Cattaneo, Riccardo Colombo, Valeria Coluccio, Maria T DeSancho, Michael E Farkouh, Valentin Fuster, Massimo Girardis, Judith S Hochman, Thomas P Jensen, Vivekanand Jha, Peter Jüni, Ajay J Kirtane, Patrick Lawler, Grégoire Le Gal, Ramon Lecumberri, Steven R Lentz, Renato D Lopes, Elizabeth Lorenzi, Marco Marietta, Carlos Henrique Miranda, Nuccia Morici, Susan C Morpeth, David A Morrow, Zoe K McQuilten, Nuria Muñoz-Rivas, Matthew D Neal, Suman Pant, Sahil A Parikh, Usha Perepu, Parham Sadeghipour, Sanjum Sethi, Michelle Sholzberg, Alex C Spyropoulos, Gregg W Stone, Azita Hajhossein Talasaz, Steven Tong, James Totterdell, Balasubramanian Venkatesh, Maddalena Alessandra Wu, Ryan Zarychanski, Stephane Zuily, Julie Viry, Jamie Rylance, Neill K J Adhikari, Janet V Diaz, John C Marshall, Jonathan A C Sterne, Srinivas Murthy
{"title":"COVID-19住院患者抗凝治疗：系统回顾和前瞻性荟萃分析","authors":"Claire L Vale, Peter J Godolphin, David J Fisher, Julian P T Higgins, Alexandra McAleenan, Francesca Spiga, Tobias Tritschler, Pedro Gabriel Melo de Barros E Silva, David D Berg, Jeffrey S Berger, Lindsay R Berry, Behnood Bikdeli, Marc Blondon, Erin A Bohula, Marco Cattaneo, Riccardo Colombo, Valeria Coluccio, Maria T DeSancho, Michael E Farkouh, Valentin Fuster, Massimo Girardis, Judith S Hochman, Thomas P Jensen, Vivekanand Jha, Peter Jüni, Ajay J Kirtane, Patrick Lawler, Grégoire Le Gal, Ramon Lecumberri, Steven R Lentz, Renato D Lopes, Elizabeth Lorenzi, Marco Marietta, Carlos Henrique Miranda, Nuccia Morici, Susan C Morpeth, David A Morrow, Zoe K McQuilten, Nuria Muñoz-Rivas, Matthew D Neal, Suman Pant, Sahil A Parikh, Usha Perepu, Parham Sadeghipour, Sanjum Sethi, Michelle Sholzberg, Alex C Spyropoulos, Gregg W Stone, Azita Hajhossein Talasaz, Steven Tong, James Totterdell, Balasubramanian Venkatesh, Maddalena Alessandra Wu, Ryan Zarychanski, Stephane Zuily, Julie Viry, Jamie Rylance, Neill K J Adhikari, Janet V Diaz, John C Marshall, Jonathan A C Sterne, Srinivas Murthy","doi":"10.7326/ANNALS-24-00800","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent.</p><p><strong>Purpose: </strong>To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes.</p><p><strong>Data sources: </strong>Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language.</p><p><strong>Study selection: </strong>Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation.</p><p><strong>Data extraction: </strong>20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding.</p><p><strong>Data synthesis: </strong>Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; <i>I</i> <sup>2</sup> = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; <i>I</i> <sup>2</sup> = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; <i>I</i> <sup>2</sup> = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding.</p><p><strong>Conclusion: </strong>Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely.</p><p><strong>Primary funding source: </strong>No direct funding. (PROSPERO: CRD42020213461).</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"59-69"},"PeriodicalIF":19.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.\",\"authors\":\"Claire L Vale, Peter J Godolphin, David J Fisher, Julian P T Higgins, Alexandra McAleenan, Francesca Spiga, Tobias Tritschler, Pedro Gabriel Melo de Barros E Silva, David D Berg, Jeffrey S Berger, Lindsay R Berry, Behnood Bikdeli, Marc Blondon, Erin A Bohula, Marco Cattaneo, Riccardo Colombo, Valeria Coluccio, Maria T DeSancho, Michael E Farkouh, Valentin Fuster, Massimo Girardis, Judith S Hochman, Thomas P Jensen, Vivekanand Jha, Peter Jüni, Ajay J Kirtane, Patrick Lawler, Grégoire Le Gal, Ramon Lecumberri, Steven R Lentz, Renato D Lopes, Elizabeth Lorenzi, Marco Marietta, Carlos Henrique Miranda, Nuccia Morici, Susan C Morpeth, David A Morrow, Zoe K McQuilten, Nuria Muñoz-Rivas, Matthew D Neal, Suman Pant, Sahil A Parikh, Usha Perepu, Parham Sadeghipour, Sanjum Sethi, Michelle Sholzberg, Alex C Spyropoulos, Gregg W Stone, Azita Hajhossein Talasaz, Steven Tong, James Totterdell, Balasubramanian Venkatesh, Maddalena Alessandra Wu, Ryan Zarychanski, Stephane Zuily, Julie Viry, Jamie Rylance, Neill K J Adhikari, Janet V Diaz, John C Marshall, Jonathan A C Sterne, Srinivas Murthy\",\"doi\":\"10.7326/ANNALS-24-00800\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent.</p><p><strong>Purpose: </strong>To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes.</p><p><strong>Data sources: </strong>Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language.</p><p><strong>Study selection: </strong>Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation.</p><p><strong>Data extraction: </strong>20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding.</p><p><strong>Data synthesis: </strong>Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; <i>I</i> <sup>2</sup> = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; <i>I</i> <sup>2</sup> = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; <i>I</i> <sup>2</sup> = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding.</p><p><strong>Conclusion: </strong>Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely.</p><p><strong>Primary funding source: </strong>No direct funding. (PROSPERO: CRD42020213461).</p>\",\"PeriodicalId\":7932,\"journal\":{\"name\":\"Annals of Internal Medicine\",\"volume\":\" \",\"pages\":\"59-69\"},\"PeriodicalIF\":19.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7326/ANNALS-24-00800\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7326/ANNALS-24-00800","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
Background: Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent.
Purpose: To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes.
Data sources: Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language.
Study selection: Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation.
Data extraction: 20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding.
Data synthesis: Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; I2 = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; I2 = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; I2 = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding.
Conclusion: Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely.
Primary funding source: No direct funding. (PROSPERO: CRD42020213461).
期刊介绍：
Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
